Clinical efficacy: After treatment, the functional symptoms decreased from 100% that infected to 46.7% without symptoms of nasal itching; 44.4% had no symptoms of sneezing; 37.8% had a mild degree of runny nose; 42.2% had no symptoms of nasal congestion; b. Subclinical efficacy: The rate of patients with strong positive skin test decreased after treatment but was not statistically significant (p> 0.05); The proportion of patients with reactive decomposition of Mastocyte is strongly reduced after treatment but not statistically significant (p> 0.05); Total IgE content, total IgG in each patient changed statistically insignificantly compared to before treatment (p> 0.05).